Promising combo therapy aims to beat B-ALL without transplant
NCT ID NCT02877303
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding two immunotherapy drugs (blinatumomab and inotuzumab ozogamicin) to a standard chemotherapy regimen (Hyper-CVAD) can improve outcomes for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The study plans to enroll 80 participants and will measure how long patients remain cancer-free, overall survival, and side effects. The goal is to see if this combination works better than chemotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab, inotuzumab ozogamicin, and combination chemotherapy (Hyper-CVAD regimen)
- What this could lead to
- If successful, this could offer a more effective first-line treatment for B-ALL, potentially improving relapse-free survival and reducing the need for stem cell transplant.
- What could go wrong
- This is an early phase II trial with only 80 participants, so results may not apply to all patients. The combination therapy also carries risks of serious side effects from both chemotherapy and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Engineered immune cells take aim at tough childhood leukemia
- New combo aims to wipe out hidden leukemia cells
- Could a One-Time immune cell infusion help older leukemia patients avoid harsh chemo?
- New CAR-T therapy aims to outsmart resistant blood cancers
- New combo therapy aims to outsmart leukemia in older patients